Upgrade to SI Premium - Free Trial

Moleculin Biotech (MBRX)

2.08 -0.02 (0.95%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Moleculin CEO discusses early MIRACLE trial data in investor segment July 6, 2026 8:33 AM - StreetInsider Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment July 6, 2026 8:33 AM - Globe NewsWire Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment July 6, 2026 8:33 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Jun 30 June 30, 2026 8:30 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Jun 30 June 30, 2026 8:30 AM - SEC Filing Moleculin reports interim AML trial data showing higher remission rates June 30, 2026 8:30 AM - StreetInsider Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control June 30, 2026 8:30 AM - StreetInsider Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: PICKER DONALD H June 24, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: KLEMP WALTER V June 24, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: Foster Jonathan P. June 24, 2026 9:00 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Jun 05 June 5, 2026 8:30 AM - SEC Filing Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML June 5, 2026 8:29 AM - Globe NewsWire Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML June 5, 2026 8:29 AM - StreetInsider Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment June 4, 2026 8:31 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 29 May 29, 2026 9:26 AM - SEC Filing Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits May 29, 2026 8:21 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 26 May 26, 2026 8:01 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: May 22 May 22, 2026 4:01 PM - SEC Filing Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting May 21, 2026 5:02 PM - StreetInsider Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin May 21, 2026 5:02 PM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: May 15 May 15, 2026 8:31 AM - SEC Filing Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial May 15, 2026 8:30 AM - Globe NewsWire Form 10-Q Moleculin Biotech, Inc. For: Mar 31 May 14, 2026 4:01 PM - SEC Filing Moleculin nears data unblinding for leukemia drug trial May 13, 2026 8:03 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 13 May 13, 2026 8:01 AM - SEC Filing Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks May 13, 2026 8:00 AM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: May 12 May 12, 2026 9:30 AM - SEC Filing Moleculin's Annamycin shows no significant heart toxicity in leukemia study May 12, 2026 9:30 AM - StreetInsider Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits May 12, 2026 9:30 AM - Globe NewsWire Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits May 12, 2026 9:30 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 08 May 8, 2026 8:45 AM - SEC Filing Moleculin Biotech receives Hong Kong patent for Annamycin reconstitution method May 8, 2026 8:45 AM - StreetInsider Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin May 8, 2026 8:45 AM - Globe NewsWire Full Article List